SPDR SP is trading at 88.29 as of the 17th of March 2025. This is a 1.33 percent increase since the beginning of the trading day. The etf's open price was 87.13. SPDR SP has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on June 13, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of SPDR SP Biotech's common stock.
In seeking to track the performance of the SP Biotechnology Select Industry Index , the fund employs a sampling strategy. SP Biotech is traded on NYSEARCA Exchange in the United States. More on SPDR SP Biotech
State Street Global Advisors Funds Distributors, LLC
Portfolio Manager
Michael Feehily, Karl Schneider, Raymond Donofrio
Transfer Agent
State Street Bank and Trust Company
Fiscal Year End
30-Jun
Exchange
NYSE Arca, Inc.
Number of Constituents
154
Market Maker
Virtu Financial
Total Expense
0.35
Management Fee
0.35
Country Name
USA
Returns Y T D
(3.25)
Name
SPDR SP Biotech ETF
Currency Code
USD
Open Figi
BBG000MQQ963
In Threey Volatility
26.34
1y Volatility
19.82
200 Day M A
95.1118
50 Day M A
90.1064
Code
XBI
Updated At
17th of March 2025
Currency Name
US Dollar
SPDR SP Biotech [XBI] is traded in USA and was established 2006-01-31. The fund is classified under Health category within SPDR State Street Global Advisors family. The entity is thematically classified as Sector ETFs. SPDR SP Biotech at this time have 7.34 B in net assets. , while the total return for the last 3 years was 2.4%.
Check SPDR SP Probability Of Bankruptcy
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in SPDR SP. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
When determining whether SPDR SP Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SPDR SP's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spdr Sp Biotech Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Spdr Sp Biotech Etf:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in SPDR SP Biotech. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
The market value of SPDR SP Biotech is measured differently than its book value, which is the value of SPDR that is recorded on the company's balance sheet. Investors also form their own opinion of SPDR SP's value that differs from its market value or its book value, called intrinsic value, which is SPDR SP's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SPDR SP's market value can be influenced by many factors that don't directly affect SPDR SP's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SPDR SP's value and its price as these two are different measures arrived at by different means. Investors typically determine if SPDR SP is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SPDR SP's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.